Moderna ได้รับการอนุมัติจากสหภาพยุโรปสำหรับ mNEXSPIKE และ mCOMBRIAX

ข้อความจากแหล่งที่มา

EX-99.1 2 exhibit9912026q1pressrelea.htm EX-99.1 Document Exhibit 99.1 Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets Reports first quarter GAAP net loss of $(1.3) billion and GAAP EPS of $(3.40), including $0.9 billion non-recurring litigation settlement charge Reiterates plan to deliver up to 10% revenue growth and GAAP operating expense reductions in 2026, excluding the non-recurring litigation settlement charge Advanced infectious disease portfolio with key regulatory milestones in the EU, including approval of mNEXSPIKE and mCOMBRIAX, Moderna’s flu plus COVID combination vaccine Initiated Phase 3 clinical study evaluating intismeran au

SEC 8-K